Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.

Abstract

Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.

• Authors: Jesus G Berdeja, Jacob P Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G Richardson, Ajai Chari
• Journal: Clinical lymphoma, myeloma & leukemia (Clin Lymphoma Myeloma Leuk) Vol. 21 Issue 11 Pg. 752-765 (11 2021) ISSN: 2152-2669 [Electronic] United States
• PMID: 34340951 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Histone Deacetylase Inhibitors
• Panobinostat

Topics

• Histone Deacetylase Inhibitors (pharmacology, therapeutic use)
• Humans
• Multiple Myeloma (drug therapy)
• Panobinostat (pharmacology, therapeutic use)